IMG Pharmaceutical has entered into a definitive agreement to acquire Matsumoto Pharmaceutical, a Japanese pharmaceutical manufacturer.

This integration combines IMG Pharma's biopharmaceutical and translational capabilities with Matsumoto Pharmaceutical's manufacturing foundation and OTC product system, forming a multi-layered product capability structure. It is expected to support the development of a scalable pharmaceutical and health product platform addressing long-term health management needs.

"This agreement is not only an important step in strengthening IMG Pharma's pharmaceutical and product platform, but also reflects our broader approach to building a structured system that connects scientific innovation with real-world healthcare applications," said Yuki Sakurai, CEO, IMG Pharma.

"By integrating Kobe-based R&D and translational capabilities with Matsumoto Pharmaceutical's established manufacturing and OTC system, we are creating a more scalable pathway from clinical care to product-based health solutions, with a continued focus on long-term health management."

IMG Medical Group operates an integrated healthcare platform across Asia, providing structured clinical services and long-term health management across the full lifecycle of care—from life creation and optimisation to preservation. Within this framework, IMG Pharma serves as the group's pharmaceutical and product platform, translating clinical needs and medical pathways into standardised, scalable pharmaceutical and health products.